调节外科手术期间心室刺激能力
Kimberly Howard-Quijano1, Yuki Kuwabara1
1Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, Biomedical Science Tower, Pittsburgh, PA, USA.
Anesthesiology clinics
|May 10, 2025
概括
心律不整会增加患者的风险. 自主神经系统的不平衡会增加心肌刺激性,导致心室动脉节律失调,这种情况可以通过外科手术来治疗.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 生理学 生理学 生理学
背景情况:
- 心律失常对患者的发病率和死亡率有很大影响.
- 心室心律失常是基质,电生理学和触发物之间的复杂相互作用的结果.
- 自主神经系统失衡会增加心肌刺激能力,这是心室动脉节律失调的一个关键因素.
研究的目的:
- 在外科手术环境中探索心肌刺激性和心室心律失常的调节.
- 了解自主神经系统失衡在心律失常中的作用.
主要方法:
- 对心脏电生理学和外科手术期间管理的现有文献的审查.
- 分析影响心肌刺激性和心律失常的因素.
- 检查影响心脏功能的麻醉和手术技术.
主要成果:
- 周术管理策略可以调节心肌刺激性.
- 血液动力学和生理学控制影响心室心律失常.
- 麻醉剂和区域技术对心脏电生理学产生影响.
结论:
- 外科手术期间的干预提供了一种管理心肌刺激性和心室节律失常的方法.
- 了解这些调制对于减少心脏病发病率和死亡率至关重要.
- 针对自主神经系统失衡,可以预防外科手术期间心律不整.
相关概念视频
Pathophysiology of Cardiac Performance
488
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
488
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
648
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
648
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273


